Here’s What Competition Looks Like In India’s Humira Biosimilars Market
Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.
You may also be interested in...
Sun’s Ilumya is available in the US and Europe, with China now on the launch radar as well. Scrip examines whether the firm’s home turf India should also be among the early markets for the novel psoriasis asset, amid pressure to maintain the 'price line'.
Lilly’s Olumiant has hit the Indian market, upping the level of competition in a rheumatoid arthritis sector that already includes the fellow JAK inhibitor Xeljanz from Pfizer and at least half a dozen biosimilar versions of Humira, among other products. But could pricing cloud Olumiant’s uptake?
Led by eight-week, pan-genotypic combo Mavyret, AbbVie’s HCV franchise grows despite a declining US market that has taken a toll on competitors Gilead and Merck. Still, AbbVie expects a falloff in the third quarter.